{
  "url": "https://struct.news/briefs/grails-former-owner-still-occupies-nearly-every-seat-at-the-table",
  "title": "GRAIL’s former owner still occupies nearly every seat at the table",
  "summary": "Illumina is disclosed as GRAIL’s sole sequencer supplier, customer, partner, former owner and source of $932.3 million in cash.",
  "published_at": "2026-08-26T23:47:41.744371+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "GRAIL, Inc.",
    "ticker": "GRAL",
    "cik": null,
    "sector": "Healthcare",
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "TWST",
      "value": "TWST",
      "display": "TWST",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ILMN",
      "value": "ILMN",
      "display": "ILMN",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    },
    {
      "group": "GRAIL’s disclosed Illumina web",
      "label": "ABT",
      "value": "ABT",
      "display": "ABT",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-26"
      }
    }
  ],
  "watch_next": [
    {
      "type": "demand",
      "statement": "Caris said higher clinical case volume, reimbursement, and average selling prices from enhanced contracting drove revenue growth.",
      "importance": "medium",
      "evidence": "The increase was driven primarily by higher clinical case volume and higher reimbursement, including improved average selling prices resulting from enhanced contracting.",
      "source_date": "2026-08-05"
    },
    {
      "type": "demand",
      "statement": "Management attributes test-volume growth to expanded prenatal sales capacity, while the latest period showed only 1.0% revenue growth.",
      "importance": "medium",
      "evidence": "The increase in test volume was driven by higher volumes of our prenatal tests primarily as a result of expansion of our sales force for our prenatal products.",
      "source_date": "2026-08-05"
    },
    {
      "type": "demand",
      "statement": "Inventory grew faster than revenue, with management linking the latest build to anticipated demand.",
      "importance": "medium",
      "evidence": "inventories of $6.9 million to support anticipated demand",
      "source_date": "2026-08-03"
    },
    {
      "type": "demand",
      "statement": "Rapid and Molecular Diagnostics sales decreased 8.8% (ex-FX) in 1H2026, attributed to lower demand for respiratory virus tests from a weaker respiratory virus season.",
      "importance": "medium",
      "evidence": "In Rapid and Molecular Diagnostics, sales decreased 8.8 percent in the first six months of 2026, excluding the impact of foreign exchange, primarily reflecting lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.",
      "source_date": "2026-07-28"
    }
  ],
  "related_tickers": [
    "ABT",
    "BLLN",
    "CAI",
    "GH",
    "GRAL",
    "ILMN",
    "PSNL",
    "TWST"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}